Connect with us

Hi, what are you looking for?

Monday, Mar 4, 2024
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.


Texas, Connecticut Expand Medical Pot Programs; Ohio Delays Expansion

Texas makes hemp legal to grow and sell, while expanding medical pot; Connecticut adds new treatable conditions; Ohio rejects marijuana as treatment for depression and insomnia

Three U.S. states made key decisions surrounding medical marijuana and hemp legislation recently including Texas, Connecticut and Ohio.
Three U.S. states made key decisions surrounding medical marijuana and hemp legislation recently including Texas, Connecticut and Ohio.

Three U.S. states made key decisions surrounding medical marijuana and hemp legislation in the last week.


The Lone Star State made some big steps in cannabis legislation this week after making a breakthrough decision to allow hemp production. Texas, the second largest state by land mass, made the legal distinction between hemp and marijuana, and is expected to be a large producer of hemp. The state will also now allow CBD products on store shelves.

Meanwhile, Gov. Greg Abbott signed a new law to expand the state’s medical marijuana program Friday. The House Bill 3703 became effective immediately and now allows patients to obtain a prescription for cannabis to treat more conditions, including multiple sclerosis, autism, ALS, terminal cancer and seizure disorders.

State lawmakers wanted to add a larger number of conditions on the list, but including more increased the chance of the bill failing to pass. For conservative Texas, these moves are still seen by advocates as steps forward for cannabis legislation.


Connecticut’s Board of Physicians recently agreed to expand the conditions of its medical marijuana program as well. It added Interstitial cystitis, Intractable Neuropathic pain, Medial arcuate ligament syndrome, Tourette syndrome and Vulvodynia and vulvar burning. The additions still need to be approved by the Regulations Review Committee but with more than 30 conditions already covered in the program, there clearly has been a desire to grow the program to help meet the needs of patients.

One condition that might be added at a later date is chronic pain, which physicians said is too broadly defined and needs further discussion before being included onto the list of approved conditions.

Connecticut isn’t a large market for medical marijuana with the program serving just 30,000 patients. Neighboring Massachusetts has a broader medical cannabis program, which could draw out-of-town patients, but it is still illegal to carry cannabis over state lines.


In other news, Ohio lawmakers rejected using marijuana as a possible treatment option for multiple conditions, including opioid use disorder, depression and insomnia. Although advocates are pushing for medical pot to help the opioid problem in the state, the medical board cited a lack of proof:

This is a science-based board. And the last thing we want to do is grasp at something to solve this crisis that may exacerbate it in a way that we’re not aware of because we don’t have the science behind it.

— Betty Montgomery, board member

While some evidence was given to show marijuana was effective in treating those three conditions, the board didn’t feel there was enough evidence to justify an approval.  If medical marijuana was approved to treat opioids but didn’t help, then it wouldn’t be possible to undo their decision.

Although there is anecdotal and suggestive evidence for marijuana to treat a range of medical conditions, a lack of concrete proof means lawmakers and physicians often take a conservative approach and deny it until more evidence is available.

1 Comment

1 Comment

  1. Missouri CBD

    August 28, 2020 at 8:11 am

    I will be sharing.

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like


Tesla CEO Elon Musk announces plans to relocate Tesla's incorporation to Texas amid legal challenges


Sampling yielded an average concentration of 638 milligrams per litre, more than three times higher than other sites in North America


'This will be the first new U.S.-owned uranium enrichment plant to begin production since 1954,' says the company's CEO


The new miners are scheduled for delivery starting in December 2023 with full deployment for Q1, 2024